These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32012701)

  • 1. Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter?
    Martin AC; Kyheng M; Foissaud V; Duhamel A; Marijon E; Susen S; Godier A
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Running after Activated Clotting Time Values in Patients Receiving Direct Oral Anticoagulants: A Potentially Dangerous Race. Results from a Prospective Study in Atrial Fibrillation Catheter Ablation Procedures.
    Benali K; Verain J; Hammache N; Guenancia C; Hooks D; Magnin-Poull I; Toussaint-Hacquard M; de Chillou C; Sellal JM
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
    Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
    Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters.
    Muller M; Godet J; Delabranche X; Sattler L; Millard D; Marzak H; Mertes PM; Steib A; Grunebaum L; Jesel L; Tacquard CA
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy.
    Zeljkovic I; Brusich S; Scherr D; Velagic V; Traykov V; Pernat A; Anic A; Szavits Nossan J; Jan M; Bakotic Z; Pezo Nikolic B; Radeljic V; Bojko A; Benko I; Manola S; Pavlovic N
    Clin Cardiol; 2021 Aug; 44(8):1177-1182. PubMed ID: 34196416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
    Negro F; Caravelli P; Morganti R; Casini M; Ruocco L; Tripodi A; De Caterina R
    Vascul Pharmacol; 2022 Jun; 144():106994. PubMed ID: 35436607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
    Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
    Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
    Hardy M; Douxfils J; Dincq AS; Sennesael AL; Xhaet O; Mullier F; Lessire S
    Front Cardiovasc Med; 2022; 9():864899. PubMed ID: 35425821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation.
    Harada M; Motoike Y; Nomura Y; Nishimura A; Koshikawa M; Murayama K; Ohno Y; Watanabe E; Izawa H; Ozaki Y
    J Arrhythm; 2020 Jun; 36(3):417-424. PubMed ID: 32528566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure.
    Kawaji T; Morimoto T; Aizawa T; Hojo S; Kushiyama A; Yaku H; Nakatsuma K; Kaneda K; Kato M; Yokomatsu T; Miki S; Kimura T
    J Clin Pharmacol; 2022 Jun; 62(6):792-800. PubMed ID: 34921561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs.
    Sairaku A; Morishima N; Matsumura H; Amioka M; Maeda J; Watanabe Y; Nakano Y
    J Interv Card Electrophysiol; 2021 Sep; 61(3):551-557. PubMed ID: 32808083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of different anticoagulation therapies on heparin dosage applied to atrial fibrillation patients undergoing atrial fibrillation catheter ablation].
    Yang L; Gao LJ; Yin XM; Guo BL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Aug; 47(8):602-607. PubMed ID: 31434430
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs.
    Maury P; Belaid S; Ribes A; Voglimacci-Stephanopoli Q; Mondoly P; Blaye M; Mandel F; Monteil B; Carrié D; Galinier M; Bongard V; Rollin A; Voisin S
    J Arrhythm; 2020 Aug; 36(4):644-651. PubMed ID: 32782635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.